Why Europe’s Alzheimer’s testing pathway could shift after Fujirebio’s latest CE marking
Alzheimer’s testing needs scale, not just science. Fujirebio’s CE-marked pTau 217 assay pushes blood biomarkers closer to routine care.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Why the FDA breakthrough pathway matters for Laguna Diagnostics’ psychiatric test
Psychiatry needs objective diagnostics. Laguna Diagnostics now faces the harder test: proving mRNA biomarkers can scale in real care.
Medical Devices & Diagnostics
What Spear Bio’s new pTau 217 assay reveals about where Alzheimer’s biomarker detection is heading
Spear Bio debuts BD-pTau 217, alpha-synuclein and pS129-a-syn assays at AD/PD 2026. What the claims mean for Alzheimer's and Parkinson's research. Read the analysis.
Medical Devices & Diagnostics
C2N Diagnostics advances PrecivityTauDx programme as tangle biomarker gains Phase 3 evidence
C2N's eMTBR-tau243 plasma assay shows independent prognostic value in Phase 3 Evoke data. What this means for Alzheimer's patient selection. Read the analysis.
Medical Devices & Diagnostics
Lucent Diagnostics expands cognitive biomarker reach through Life Line Screening
Lucent Diagnostics partners with Life Line Screening to expand Alzheimer’s blood testing nationwide. Discover what this means for early detection.
Medical Devices & Diagnostics
Can EpiSwitch PSE become more than a diagnostic tool in prostate disease management?
Doctors Studio’s ozone pilot shows promising 30-day shifts in prostate biomarkers tracked via EpiSwitch PSE. Could this reshape trial design? Find out.